Q2 2012 Results (Lundbeck) - Aug 8, 2012 - Anticipated launch in 10-15 additional countries for schizophrenia in H2 2012; P3 program is ongoing for zicronapine focusing on schizophrenia will enroll around 160 patients and company is planning to include additional P3 studies which will investigate benefit and risk profile
Anticipated launch • Clinical protocol • Schizophrenia
|
|
Sycrest (asenapine)
---
Sycrest®/Saphris® (asenapine) is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in the EU (Sycrest), and for the treatment of schizophrenia and/or moderate to severe manic episodes associated with bipolar I disorder outside the EU (Saphris). Lundbeck has now launched Sycrest/Saphris in 18 countries, with around 10-15 additional commercial launches expected in the second half of 2012. Lundbeck retains commercial rights to Sycrest / Saphris in all markets outside the US, Japan and China. Revenue from Sycrest/Saphris is recognised as part of Other pharmaceuticals.
Zicronapine
Zicronapine is in clinical development for the treatment of psychosis. The clinical phase III programme is ongoing and the first study is focused on schizophrenia and is expected to enrol 160 patients. This pivotal programme is planned to include additional phase III studies to further investigate the compound's benefit and risk profile...
(IR6)
|